Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Use of nonnucleoside reverse-transcriptase inhibitors

C D Holtzer1, R L Coleman

  • 1UCSF AIDS Program, San Francisco General Hospital, CA 94110, USA. choltzer@sfaids.ucsf.edu

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|March 10, 1998
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO).

Gynecologic oncology·2023
Same author

For ovarian cancer PARPi maintenance therapy: more is better, right?

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.

Gynecologic oncology·2021
Same author

Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

The forefront of ovarian cancer therapy: update on PARP inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2020